Exosomes Recovered From the Plasma of COVID-19 Patients Expose SARS-CoV-2 Spike-Derived Fragments and Contribute to the Adaptive Immune Response.
COVID-19
SARS-CoV-2
antigen-presenting cells (APCs)
exosomes
immune activation
soluble mediators in immunity
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
09
2021
accepted:
16
12
2021
entrez:
3
2
2022
pubmed:
4
2
2022
medline:
8
2
2022
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by beta-coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has rapidly spread across the globe starting from February 2020. It is well established that during viral infection, extracellular vesicles become delivery/presenting vectors of viral material. However, studies regarding extracellular vesicle function in COVID-19 pathology are still scanty. Here, we performed a comparative study on exosomes recovered from the plasma of either MILD or SEVERE COVID-19 patients. We show that although both types of vesicles efficiently display SARS-CoV-2 spike-derived peptides and carry immunomodulatory molecules, only those of MILD patients are capable of efficiently regulating antigen-specific CD4
Identifiants
pubmed: 35111156
doi: 10.3389/fimmu.2021.785941
pmc: PMC8801440
doi:
Substances chimiques
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
785941Informations de copyright
Copyright © 2022 Pesce, Manfrini, Cordiglieri, Santi, Bandera, Gobbini, Gruarin, Favalli, Bombaci, Cuomo, Collino, Cricrì, Ungaro, Lombardi, Mangioni, Muscatello, Aliberti, Blasi, Gori, Abrignani, De Francesco, Biffo and Grifantini.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Extracell Vesicles. 2019 Nov 4;8(1):1685634
pubmed: 31741725
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Nat Rev Immunol. 2009 Aug;9(8):581-93
pubmed: 19498381
Nat Immunol. 2010 Sep;11(9):785-97
pubmed: 20720586
Exp Mol Med. 2019 Mar 15;51(3):1-9
pubmed: 30872565
Immunotherapy. 2016 Jun;8(7):809-19
pubmed: 27349980
Cell Biosci. 2019 Feb 15;9:19
pubmed: 30815248
Vaccines (Basel). 2019 Aug 28;7(3):
pubmed: 31466253
Front Immunol. 2016 Dec 21;7:613
pubmed: 28066423
J Extracell Vesicles. 2016 Dec 23;6(1):1267896
pubmed: 28326167
PLoS Biol. 2019 Jul 18;17(7):e3000363
pubmed: 31318874
Kidney Int. 2020 Aug;98(2):314-322
pubmed: 32461141
J Extracell Vesicles. 2019 Apr 01;8(1):1596016
pubmed: 30988894
Blood. 2005 Jul 1;106(1):216-23
pubmed: 15790784
Proteomics. 2015 Aug;15(15):2597-601
pubmed: 25921073
Am J Physiol Cell Physiol. 2020 Jan 1;318(1):C29-C39
pubmed: 31693397
Viruses. 2020 May 22;12(5):
pubmed: 32456011
Sci Rep. 2021 Jan 13;11(1):1053
pubmed: 33441764
Nucleic Acids Res. 2012 Jan;40(Database issue):D1241-4
pubmed: 21989406
Pediatr Nephrol. 2019 Jan;34(1):11-30
pubmed: 29181712
J Proteome Res. 2019 Feb 1;18(2):623-632
pubmed: 30450911
J Biol Chem. 2021 Jan-Jun;296:100306
pubmed: 33476648
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11527-32
pubmed: 11553777
EBioMedicine. 2021 May;67:103369
pubmed: 33971404
Biol Open. 2016 May 15;5(5):620-30
pubmed: 27113959
Cytometry B Clin Cytom. 2004 Jul;60(1):1-13
pubmed: 15221864
Front Mol Biosci. 2021 Feb 22;8:632290
pubmed: 33693030
Int Immunol. 2005 Jul;17(7):879-87
pubmed: 15908444
Nat Methods. 2014 Mar;11(3):319-24
pubmed: 24487582
Biopolymers. 2004;76(1):66-8
pubmed: 14997476
Cell Oncol (Dordr). 2020 Oct;43(5):889-900
pubmed: 32578140
J Extracell Vesicles. 2021 Apr;10(6):e12079
pubmed: 33850608
Nat Immunol. 2017 Nov 16;18(12):1288-1298
pubmed: 29144501
Nat Rev Microbiol. 2017 Sep;15(9):559-572
pubmed: 28649136
Viral Immunol. 2005;18(1):116-26
pubmed: 15802956
Cells. 2019 Jul 15;8(7):
pubmed: 31311206
Nucleic Acids Res. 2016 Jul 8;44(W1):W147-53
pubmed: 27190236
Crit Care. 2010;14(2):R61
pubmed: 20385017
Front Immunol. 2020 May 12;11:887
pubmed: 32477358
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Mol Cell Biol. 2017 Jul 14;37(15):
pubmed: 28533221
PLoS Pathog. 2019 Aug 12;15(8):e1008002
pubmed: 31404116
Annu Rev Immunol. 2018 Apr 26;36:717-753
pubmed: 29490164
Ann N Y Acad Sci. 2012 Jul;1261:55-63
pubmed: 22823394
Sci Rep. 2020 Jan 23;10(1):1039
pubmed: 31974468
Nat Protoc. 2016 Dec;11(12):2301-2319
pubmed: 27809316
Front Cell Dev Biol. 2020 May 26;8:376
pubmed: 32528954
Nat Methods. 2018 Jun;15(6):440-448
pubmed: 29735998
J Gen Virol. 2012 Aug;93(Pt 8):1725-1730
pubmed: 22592262
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Cell Mol Life Sci. 2018 Aug;75(15):2873-2886
pubmed: 29441425
Nat Immunol. 2020 Mar;21(3):298-308
pubmed: 32066953
Cell Mol Life Sci. 2010 Jul;67(14):2363-86
pubmed: 20213276
Cell Syst. 2020 Jul 22;11(1):11-24.e4
pubmed: 32619549
Mol Cell Proteomics. 2019 May;18(5):982-994
pubmed: 30755466
J Biomol Struct Dyn. 2021 May;39(8):3034-3060
pubmed: 32351170
F1000Res. 2020 Feb 28;9:157
pubmed: 32399202
Nat Metab. 2021 Jul;3(7):909-922
pubmed: 34158670
Mol Med. 2018 Aug 30;24(1):46
pubmed: 30165816
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Nat Immunol. 2002 Dec;3(12):1156-62
pubmed: 12426563
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
EMBO Rep. 2015 Jan;16(1):24-43
pubmed: 25488940
Mol Cell Proteomics. 2012 Mar;11(3):M111.013722
pubmed: 22021278
Nucleic Acids Res. 2009 Jan;37(Database issue):D412-6
pubmed: 18940858